Allen & Overy » Life Sciences
142 FOLLOWERS
Allen & Overy is one of the world's top law firms with expertise in banking & finance, M&A, litigation, funds, IP, and related business solutions. In our blog dedicated to Life Sciences, we report on EU and national regulatory, compliance, intellectual property, and transactional developments in the sector.
Allen & Overy » Life Sciences
2M ago
In H. Lundbeck A-S v. Lupin Ltd., Case No. 2022-1194 (Fed. Circ. December 7, 2023), Plaintiffs, H. Lundbeck A/S (“Lundbeck”) and Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A ..read more
Allen & Overy » Life Sciences
2M ago
The European Commission (EC) has published its latest report on competition enforcement in medicines and medical products. ..read more
Allen & Overy » Life Sciences
3M ago
On January 10, 2024, Senators Chris Coons and Thom Tillis introduced a bill titled Improving Efficiency to Increase Competition Act (“IEICA”). The IEICA would require that the Comptroller General ..read more
Allen & Overy » Life Sciences
3M ago
In Germany and the EU, medical devices are subject to a complex and evolving regulatory framework, covering aspects such as safety, performance, clinical evaluation, labelling, post-marketing ..read more
Allen & Overy » Life Sciences
4M ago
The Biden Administration’s recent publication of the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights and its request for comments on the draft guidance will impact ..read more
Allen & Overy » Life Sciences
5M ago
The European Commission (EC) has fined five pharmaceutical companies a total of EUR13.4 million for participating in a cartel concerning N-Butylbromide Scopolamine/Hyoscine (SNBB) – an active ..read more
Allen & Overy » Life Sciences
5M ago
The UK Competition and Markets Authority (CMA) has taken the unusual step of issuing a prioritisation statement on cooperation between competitors to make combination therapies available to the NHS ..read more
Allen & Overy » Life Sciences
6M ago
The European Commission (EC) has fined five pharmaceutical companies a total of EUR13.4 million for participating in a cartel concerning N-Butylbromide Scopolamine/Hyoscine (SNBB) – an active ..read more
Allen & Overy » Life Sciences
6M ago
In increasingly complex and uncertain economic times, companies in the life sciences sector are facing unique supply chain challenges ..read more
Allen & Overy » Life Sciences
6M ago
On August 29, 2023, Health and Human Services (“HHS”) announced the first ten drugs covered by Medicare Part D selected for negotiation under President Biden’s Inflation Reduction Act of 2022 (“IRA ..read more